Specifically, APP-transgenic mice are models of the presymptomatic phase of AD with cerebral β-amyloidosis and early changes of tauopathy, but mice do not develop human-like neurofibrillary lesions and the symptomatic phase of AD. Here, APP is linked to tauopathy.